Precision BioSciences (DTIL) Projected to Post Quarterly Earnings on Wednesday

Precision BioSciences (NASDAQ:DTIL) will likely be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect Precision BioSciences to post earnings of ($2.09) per share and revenue of $4.28 million for the quarter.

Precision BioSciences Stock Performance

DTIL opened at $5.45 on Monday. The company has a market capitalization of $41.81 million, a price-to-earnings ratio of 90.85 and a beta of 1.59. The business’s 50-day moving average price is $5.14 and its two-hundred day moving average price is $6.68. Precision BioSciences has a 1 year low of $3.61 and a 1 year high of $15.97. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Wall Street Analysts Forecast Growth

DTIL has been the topic of several research reports. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research report on Wednesday, March 19th.

Insider Activity at Precision BioSciences

In other news, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total transaction of $172,033.46. Following the transaction, the chief executive officer now directly owns 107,087 shares in the company, valued at $500,096.29. The trade was a 25.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider J. Jefferson Smith sold 10,287 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total transaction of $49,274.73. Following the completion of the sale, the insider now directly owns 87,440 shares in the company, valued at approximately $418,837.60. The trade was a 10.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 8,734 shares of company stock valued at $39,946 and have sold 47,279 shares valued at $222,064. 4.00% of the stock is owned by company insiders.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.